BiotechTube

ZY19489 Capsule + Placebo Capsule

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Aug 25, 2021 → Jan 21, 2022

NCT ID
NCT05206201

About ZY19489 Capsule + Placebo Capsule

ZY19489 Capsule + Placebo Capsule is a phase 1 stage product being developed by Zydus Lifesciences for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT05206201. Target conditions include Malaria.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05206201Phase 1Completed

Competing Products

20 competing products in Malaria

See all competitors
ProductCompanyStageHype Score
SAR97276ASanofiPhase 2
51
SJ733 + CobicistatEisaiPhase 1
33
(+)-SJ000557733 (SJ733)EisaiPhase 2
52
E1018 + PlaceboEisaiPhase 1
33
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
33
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mgMerckPhase 2
52
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanilMerckPhase 1
33
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mgMerckPhase 2
52
KLU156 + CoartemNovartisPhase 3
77
KAF156NovartisPhase 2
52
KAE609 + IV Artesunate + CoartemNovartisPhase 2
52
KAE609NovartisPhase 2
52
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
65
Artemether-lumefantrine (COA566)NovartisPhase 2/3
65
INE963NovartisPhase 2
52
Ganaplacide + ItraconazoleNovartisPhase 1
33
KAE609 + Piperaquine PhosphateNovartisPhase 1
33
Artemether-lumefantrineNovartisPhase 3
77
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
52
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
52

Other Products from Zydus Lifesciences

SaroglitazarApproved
85
DesidustatApproved
85
Desidustat Oral Tablet + Epoetin AlfaPhase 3
77
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel + DUAC® Gel + PlaceboPhase 3
77
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)Phase 3
77